Submitted by Anonymous (not verified) on 31 March 2025 - 15:05
Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 14, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 14, Status: Authorised